Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 184   

Articles published

PFE 34.88 -0.23 (-0.66%)
price chart
Biosimilars: AbbVie Inc, Pfizer Inc., Amgen, Inc. Expectations
After biosimilars launched in the US, the drugmakers are feeling the heat of the competition as biosimilars are cost effective as well as they provide the same safety profile and efficacy as the branded drugs.
Analyst's Valuable Buzzers: Pfizer, Inc. (NYSE:PFE) , ARIAD Pharmaceuticals ...
Analyst's Valuable Buzzers: Pfizer, Inc. (NYSE:PFE) , ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - The following two tabs change content below.
Pfizer Inc. (NYSE:PFE) To Close Down Four Of Its Legacy Distribution Sites
Pfizer Inc. (NYSE:PFE) has opted to close down four of its legacy distribution units that it acquired in the buyout of Hospira last year.
Pfizer Inc. (NYSE: PFE) Buy Rating Reiterated at Deutsche Bank AG  BNB Daily (blog)
Pfizer, Inc. (NYSE:PFE) Updated Price Targets  FTSE News
BMO Capital Highlights Several Targets Following Pfizer Inc.'s Deal with ...
Considering Pfizer Inc.'s (NYSE:PFE) deal worth $14 billion in order to acquire Medivation Inc (NASDAQ:MDVN), analyst Do Kim at BMO Capital believes the deal has increased the attractiveness of the other mid-cap companies in the bio-tech segment.
SunTrust Banks Comments on Pfizer Inc.'s Q4 2016 Earnings (PFE)
Pfizer logo Pfizer Inc. (NYSE:PFE) - Stock analysts at SunTrust Banks dropped their Q4 2016 earnings per share (EPS) estimates for Pfizer in a research report issued on Wednesday.
Pfizer Inc.: This Tiny Biotech Stock Has WAY More Upside Than PFE Stock  Profit Confidential
Updating My Price Target On Pfizer  Seeking Alpha
Pfizer Inc. (PFE) Closes 0.14% Up on the Day for August 26
Dow Jones component Pfizer Inc. (PFE) saw its stock move 0.14% to $34.82, representing a per-share move of $0.05, on volume of 18.72 million shares for Friday.
Pfizer Beats Estimates Even as Biggest Product Falls Short
Pfizer Inc.'s biggest product, the vaccine Prevnar, fell short of sales estimates in the second quarter, though the drugmaker posted earnings that beat analysts' estimates thanks to strong sales of two of its newest drugs.
Barclay Reviews Pfizer's Second Quarter, Maintains $34 Target  Benzinga
Pfizer Inc. (NYSE:PFE) Earnings: Here's What The Numbers Say  TCC
Pfizer Inc: A Speculative, Overvalued Company
By using the ModernGraham method, one can review a company's historical accomplishments and determine an intrinsic value that can be compared across industries.
Recent Patent Ruling A Positive For Pfizer
A Federal District Court in Massachusetts recently issued a patent ruling that is "favorable" for Pfizer Inc. (NYSE: PFE), according to Gregg Gilbert of Deutsche Bank.
J&J Remicade Patent Found Invalid in U.S. Victory for Pfizer  Bloomberg
Court Says Pfizer's Biosimilar of J&J's Remicade Doesn't ...  Wall Street Journal
Medivation Inc (MDVN) Downgraded to Neutral on Pfizer Inc. (PFE) Deal
Medivation Inc. (NASDAQ:MDVN) has been downgraded at Credit Suisse following the deal with Pfizer Inc. (NYSE:PFE). Both the companies have come to a mutual consensus regarding the merger which is expected to be closed someway down the line as ...